| HCPCS | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Drug Class | Minor Drug Class | Oral (Y/N) | FDA Approval Year | FDA Discontinuation Year | CMS Effective Date | CMS Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| J9180 | Epirubicin | Epirubicin | 50 mg | Chemotherapy | Antitumor Antibiotic | Anthracycline | No | 1999 | Jan 1, 2001 | Dec 31, 2003 | No Longer Used | |
| J9328 | Temozolomide | Temodar | 1 mg | Chemotherapy | Alkylating Agent | Tetrazine | No | 1999 | Jan 1, 2010 | In Use | ||
| Q2017 | Teniposide | Teniposide | 50 mg | Chemotherapy | Plant Alkaloid | Epipodophyllotoxins | No | 1992 | Jul 1, 2000 | Jan 1, 2026 | In Use | |
| J1710 | Hydrocortisone Sodium Phosphate | Hydrocortone | 50 mg | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | No | 1960 | 2004 | Jan 1, 1982 | In Use | |
| J9211 | Idarubicin | Idamycin | 5 mg | Chemotherapy | Antitumor Antibiotic | Anthracycline | No | 1990 | Jan 1, 1993 | In Use | ||
| C9081 | Idecabtagene vicleucel | Abecma | up to 460000000 | Immunotherapy | CAR-T | BCMA | No | 2021 | Sep 27, 2021 | Jan 26, 2022 | No Longer Used | |
| J9024 | Atezolizumab, hyaluronidase-tqjs | Tecentriq Hybreza | 5mg | Immunotherapy | Checkpoint Inhibitor | PD-L1 | No | 2024 | Mar 26, 2025 | In Use | ||
| Q5148 | Filgrastim-txid (nypozi) | Nypozi | 1 microgram | Ancillary Therapy | Immunostimulant | Colony-Stimulating Factor | No | 2024 | Mar 26, 2025 | In Use | ||
| C9173 | Filgrastim-txid (nypozi) | Nypozi | 1 mcg | Ancillary Therapy | Immunostimulant | Colony-Stimulating Factor | No | 2024 | Dec 17, 2024 | Jul 9, 2025 | In Use | |
| J9266 | Pegaspargase | Oncaspar | unspecified | Chemotherapy | Miscellaneous Agent | Enzyme | No | 1994 | Jan 1, 1996 | In Use | ||
| J9092 | Cyclophosphamide | Cyclophosphamide | 2 g | Chemotherapy | Alkylating Agent | Nitrogen Mustard | No | 1959 | Jan 1, 1994 | In Use | ||
| J1260 | Dolasetron Mesylate | Anzemet | 10 mg | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | No | 1997 | Jan 1, 2000 | In Use | ||
| J9184 | Gemcitabine (avyxa) | Avgemsi | 200mg | Chemotherapy | Antimetabolite | Pyrimidine Analog | No | 2025 | Jan 1, 2026 | In Use | ||
| J9308 | Ramucirumab | Cyramza | 5mg | Immunotherapy | Monoclonal Antibody | VEGFR | No | 2014 | Jan 1, 2016 | In Use | ||
| C9416 | BCG | BCG, Intravesical | Per instillation | Immunotherapy | Biological Response Modifier | Live Vaccine | No | 1990 | Jan 1, 2004 | Dec 31, 2003 | No Longer Used | |
| J9091 | Cyclophosphamide | Cyclophosphamide | 1 g | Chemotherapy | Alkylating Agent | Nitrogen Mustard | No | 1959 | Jan 1, 1994 | Jan 1, 2011 | No Longer Used | |
| J9011 | Datopotamab Deruxtecan | Datroway | 1mg | Immunotherapy | Drug Antibody Conjugate | Topoisomerase I, TROP2 | No | 2025 | Sep 8, 2025 | In Use | ||
| C9110 | Alemtuzumab | Lemtrada | 10 mg | Immunotherapy | Monoclonal Antibody | CD52 | No | 2001 | Jan 1, 2001 | Dec 31, 2007 | No Longer Used | |
| J9022 | Atezolizumab | Tecentriq | 10mg | Immunotherapy | Checkpoint Inhibitor | PD-L1 | No | 2016 | Jan 1, 2018 | In Use | ||
| C9449 | Blinatumomab | Blincyto | 1 mcg | Immunotherapy | Monoclonal Antibody | CD3 (T cells) and CD19 (B cells) | No | 2014 | Apr 1, 2015 | In Use | ||
| J9261 | Nelarabine | Arranon | 50 mg | Chemotherapy | Antimetabolite | Purine Analog | No | 2005 | Jan 1, 2007 | In Use | ||
| J9020 | Asparaginase | Erwinaze | 10, 000 units (I.U.) | Chemotherapy | Miscellaneous Agent | Enzyme | No | 1994 | Jan 1, 1984 | Jan 1, 2026 | In Use | |
| J9021 | Asparaginase Erwinia Chrysanthemi (recombinant)-rywn | Rylaze | 0.1mg | Chemotherapy | Miscellaneous Agent | Enzyme | No | 2021 | Jan 26, 2022 | In Use | ||
| J9052 | Carmustine (Accord) | Carmustine | 100mg | Chemotherapy | Alkylating Agent | Nitrosurea | No | 2022 | Dec 7, 2023 | In Use | ||
| C9307 | Linvoseltamab-gcpt | Lynozyfic | 1mg | Immunotherapy | Bispecific Antibody | BCMA, CD3 | No | 2025 | Jan 1, 2026 | In Use |
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has
not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in
specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is
truly not available.
Home